Periplocymarin Suppresses Nonsmall Cell Lung Cancer Progression by Modulating MAPK14 Phosphorylation: An Integrated Multiomics and Preclinical Study

Nonsmall cell lung cancer (NSCLC) remains a leading malignancy with limited therapies, calling for natural product-derived anticancer candidates with well-defined mechanisms. In this study, Periplocymarin was identified as a selective anti-NSCLC candidate. Its antitumor activity was verified in cell proliferation, apoptosis, migration assays and patient-derived organoid models. To dissect its antitumor mechanism, we employed an integrated strategy combining transcriptome sequencing, network pharmacology, thermal proteome profiling (TPP), microscale thermophoresis (MST) and molecular simulations, and validated the involvement of p38α MAPK (MAPK14) phosphorylation via Western blot. Finally, the in vivo antitumor efficacy and safety of Periplocymarin were validated using nude mouse xenograft and patient-derived xenograft (PDX) models. Periplocymarin inhibited proliferation and migration and induced apoptosis in NSCLC cells in a concentration-dependent manner, while also suppressing Patient-Derived Organoid (PDO) growth. Integrated analyses and experimental validation indicated MAPK14 as a candidate target associated with Periplocymarin treatment. Periplocymarin reduced MAPK14 phosphorylation, and MAPK14 knockdown partially attenuated its antitumor effects. In vivo, Periplocymarin significantly suppressed tumor growth in nude mouse subcutaneous xenograft and PDX models, with decreased Ki-67 and phospho-MAPK14 levels and no evident toxicity. This study demonstrates Periplocymarin exerts anti-NSCLC activity via modulating MAPK14 phosphorylation, supporting its further development for NSCLC therapy.

Authors

Institutions

Publication Details

Journal
Journal of Proteome Research
Published
2026-11-18
DOI
https://doi.org/10.1021/acs.jproteome.6c00598
Primary Topic
Natural Compounds in Disease Treatment
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Periplocymarin Suppresses Nonsmall Cell Lung Cancer Progression by Modulating MAPK14 Phosphorylation: An Integrated Multiomics and Preclinical Study

Xiao Liang, Liting Lv, Jiahai Shi, X R Wang et al.
4 links
Journal of Proteome Research
Natural Compounds in Disease Treatment
article

Periplocymarin Suppresses Nonsmall Cell Lung Cancer Progression by Modulating MAPK14 Phosphorylation: An Integrated Multiomics and Preclinical Study

Xiao Liang, Liting Lv, Jiahai Shi, X R Wang, Yifei Liu, Han Sun, Yiyan Miao, Zhibin Song, Wang Mingwei, Xingqin Zhou, Xiaoting Ma
article en

Abstract

Nonsmall cell lung cancer (NSCLC) remains a leading malignancy with limited therapies, calling for natural product-derived anticancer candidates with well-defined mechanisms. In this study, Periplocymarin was identified as a selective anti-NSCLC candidate. Its antitumor activity was verified in cell proliferation, apoptosis, migration assays and patient-derived organoid models. To dissect its antitumor mechanism, we employed an integrated strategy combining transcriptome sequencing, network pharmacology, thermal proteome profiling (TPP), microscale thermophoresis (MST) and molecular simulations, and validated the involvement of p38α MAPK (MAPK14) phosphorylation via Western blot. Finally, the in vivo antitumor efficacy and safety of Periplocymarin were validated using nude mouse xenograft and patient-derived xenograft (PDX) models. Periplocymarin inhibited proliferation and migration and induced apoptosis in NSCLC cells in a concentration-dependent manner, while also suppressing Patient-Derived Organoid (PDO) growth. Integrated analyses and experimental validation indicated MAPK14 as a candidate target associated with Periplocymarin treatment. Periplocymarin reduced MAPK14 phosphorylation, and MAPK14 knockdown partially attenuated its antitumor effects. In vivo, Periplocymarin significantly suppressed tumor growth in nude mouse subcutaneous xenograft and PDX models, with decreased Ki-67 and phospho-MAPK14 levels and no evident toxicity. This study demonstrates Periplocymarin exerts anti-NSCLC activity via modulating MAPK14 phosphorylation, supporting its further development for NSCLC therapy.

Journal of Proteome Research
Xuzhou Medical College (CN), Nantong University (CN), Affiliated Hospital of Nantong University (CN), Jiangyin People's Hospital (CN), Jiangyin Traffic Planning Survey & Design Institute (China) (CN)
National Natural Science Foundation of China, Government of Jiangsu Province, Jiangsu Provincial Department of Human Resources and Social Security, Graduate Research and Innovation Projects of Jiangsu Province
Good health and well-being
Natural Compounds in Disease Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon